Agenda

All conference abstracts are available for your convenience.
Download conference abstracts

Friday, 4 May, 2012

9:00

Introduction and program overview
SrdanVerstovsek, MD, PhD, chairperson
Alessandro M. Vannucchi, MD, chairperson

9:10

Pre-activity audience survey

Session I: Biology of Myeloproliferative Diseases and Myelodysplastic Syndromes

9:20

High-throughput approach to the MPN and MDS genome
Robert Kralovics, PhD

9:50

Mutations in MPN: which ones matter?
Stefan Constantinescu, MD, PhD

10:20

Does STAT make a difference in ET & PV?
Anthony R. Green, PhD, FRCP, FRCPath

10:50

Coffee break

11:10

TET2 in MPN and MDS: what is the role?
Francois Delhommeau, MD, PhD

11:40

JAK/STAT signaling and mechanisms of resistance to JAK2 inhibitors
Laurent Knoops, MD, PhD

12:10

Should molecular genetics guide individualized therapy in MDS?
Felicitas Thol, MD

12:40

Lunch

Session II: Clinical Aspects of Myelodysplastic Syndromes

14:10

A practical approach to risk stratification of MDS
Mario Cazzola, MD

14:40

Medical therapies for MDS: who to treat, when and with what
Jaroslav Cermak, MD, PhD

15:10

Coffee break

15:30

New therapies for MDS beyond hypomethylating agents and IMiDs
Valeria Santini, MD

16:00

Stem cell transplantation for advanced MDS: where we stand
Theo De Witte, MD, PhD

16:30

MDS/MPD overlap syndromes
Evangelos Terpos, MD

17:00

Closing remarks and post-activity audience survey

17:15

Adjourn

Saturday, 5 May, 2012

9:00

Welcome and pre-activity audience survey

Session III: Clinical Aspects of Polycythemia Vera and Essential Thrombocythemia

9:10

Natural history of strictly WHO-defined PV and ET: implications for everyday practice
Tiziano Barbui, MD

9:40

Leukemic transformation: therapy-related or unrelated?
Jean Jacques Kiladjian, MD, PhD

10:10

Are all interferons the same for MPN?
Richard T. Silver, MD

10:40

Coffee break

11:00

A critical reappraisal of anagrelide in the management of ET
Heinz Gisslinger, MD

11:30

Position of JAK inhibitors in PV and ET current treatment landscape
Srdan Verstovsek, MD, PhD

12:00

Lunch symposium
“JAK2 Inhibition in Myelofibrosis: What Can We Expect in the Clinic?”
Supported by Novartis

Session IV: Clinical Aspects of Myelofibrosis

13:30

A practical approach to risk stratification for PMF: IPSS to DIPPS-plus
Francisco J. Cervantes, MD, PhD

14:00

Splanchnic vein thrombosis: typical or atypical MPN?
Giovanni Barosi, MD

14:30

Anemia in myelofibrosis: role of IMIDs
Hans Hasselbalch, MD

15:00

Coffee break

15:20

JAK inhibitors in MF
Claire N. Harrison, MD

15:50

Stem cell transplantation for MF: where we stand
Nicolaus Kröger, MD

16:20

Novel drugs for myelofibrosis
Alessandro M. Vannucchi, MD

16:50

Closing remarks and post-activity audience survey

17:00

Adjourn